Purminds

What Purminds does

PurMinds NeuroPharma Inc. (now operating as PurMinds Enterprises, Inc. following a November 2025 reverse takeover with Pacific Software, Inc., OTC: PFSF) is a clinical-stage neuroscience company that pairs photonic chip-based point-of-care diagnostics with disease-modifying neurotherapeutics. The diagnostic arm, branded PurPrecision, is built around SpectroChip photonic chip technology integrated with lateral flow immunoassay (LFIA) platforms and is marketed as detecting 300 biomarkers in 10 minutes with hospital-level accuracy, portability, and cloud connectivity; near-term diagnostic revenue is expected to begin in 2026 via an exclusive partnership with SpectroChip Global Inc. The therapeutic arm, the PurQuest Pipeline, is split between the PUR100 series of botanical neuroplastogens (including PUR102, a botanical psilocybin candidate in IND filing for anxiety in cancer patients) and the PUR500 series of novel small molecules engineered from psychedelic scaffolds (including PUR501, a non-hallucinogenic neuroplastogen in pre-clinical development for Mild Cognitive Impairment).

The company operates a 20,000 sq. ft. GMP-compliant NeuroLabs facility in Burlington, Ontario, and is headquartered at 1235 Bay Street, Toronto, under PurMinds NeuroPharma Inc. (10763942 Canada Inc.), with a Health Canada Dealer's License for Controlled Drugs and Substances and an IND submission underway in partnership with a leading U.S. hospital network. Revenue mechanics span hardware sales and leasing of SpectroChip devices, recurring consumable test-kit revenue, controlled-substances supply agreements with distributors such as Bluestem API, and future licensing/royalty potential on PUR102 and PUR501. IP protection rests on 45 patents worldwide covering SpectroChip photonic chip design and POCT manufacturing, plus proprietary trademarks. The Scientific Advisory Board includes Dr. Alan Kozikowski (550+ publications, 100+ patents), SpectroChip inventor Dr. Kevin Ko, and three Mayo Clinic specialists, supporting a research-driven, capital-light go-to-market that relies on enterprise partnerships, industry conferences, and educational content rather than a traditional sales force.

Name

Purminds

Legal name

PurMinds NeuroPharma Inc.

Website

https://purminds.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

PurMinds NeuroPharma is a clinical-stage neuropharma company developing disease-modifying therapeutics (PUR102 botanical neuroplastogen, PUR501 non-hallucinogenic NCE) alongside photonic chip-based point-of-care diagnostics (PurPrecision/SpectroChip), serving patients with cancer-related anxiety, neurodegenerative diseases, and Mild Cognitive Impairment.

Ownership category

akta.pro rank

Product category

Clinical-stage Neuropharma and Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516), Biological Product (except Diagnostic) Manufacturing (325414), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)

akta.pro secondary industry

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

Keywords

• Clinical-stage neurotherapeutics
• Point-of-care diagnostics
• Neuroplastogen drug development
• Photonic chip biosensing
• Neurological disease therapeutics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Point-of-Care Diagnostic Solutions: Revenue from SpectroChip photonic chip-based diagnostic devices and associated test kits for point-of-care testing. Partnership expected to generate near-term revenue in 2026.
2. Diagnostic Device Leasing: Leasing model for SpectroChip diagnostic devices to healthcare facilities, creating recurring revenue from equipment deployment.
3. Therapeutic Development and Licensing: Revenue from development and potential licensing of disease-modifying neurotherapeutics including PUR102 and PUR501 for neurological disorders.
4. Recurring Test-Kit Revenue: Recurring revenue from consumable test kits used with the SpectroChip diagnostic platform in healthcare settings.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

PurMinds is a clinical-stage neuropharma company developing disease-modifying neurotherapeutics and point-of-care diagnostic solutions for neurological and neurodegenerative disorders. Its core offerings include the PurQuest Pipeline of botanical neuroplastogens and novel small molecules (PUR102 for anxiety in cancer patients, PUR501 for Mild Cognitive Impairment), the PurPrecision diagnostic platform built on SpectroChip photonic chip technology for biomarker detection, and GMP-compliant NeuroLabs research and manufacturing capabilities.

Product overview

PurMinds NeuroPharma operates as a clinical-stage neurotherapeutics company with a platform architecture combining disease-modifying therapeutics and diagnostic solutions. The core product portfolio includes PurPrecision (photonic chip-based point-of-care diagnostics), the PurQuest Pipeline (PUR100 Series botanical neuroplastogens and PUR500 Series novel small molecules), and NeuroLabs (20,000 sq. ft. GMP-compliant research facility). The therapeutic pipeline focuses on PUR102 (botanical psilocybin, IND filing stage) for anxiety in cancer patients and PUR501 (non-hallucinogenic neuroplastogen, pre-clinical) for Mild Cognitive Impairment. In partnership with SpectroChip Global, the company integrates photonic chip technology for point-of-care biomarker detection and multi-omics data analysis.

Differentiator

Problem solved

Functional benefit

Brands

• PurPrecision™: Advanced diagnostic solutions powered by photonic chip-based point-of-care testing technology with hospital-level accuracy, portability, and cloud connectivity.
• PurQuest™ Pipeline
• NeuroLabs

Products and services

• PurPrecision Advanced diagnostic solutions powered by photonic chip-based point-of-care testing technology offering hospital-level accuracy with portability and cloud connectivity. Integrates biomarker intelligence and multi-omics data for the 4P precision medicine model, capable of detecting 300 biomarkers in 10 minutes. Distributed to healthcare providers via exclusive partnership with SpectroChip Global with expected near-term revenue generation in 2026.
• PUR100 Series (PurQuest Pipeline) Proprietary neuroplastogen formulations including botanical psilocybin targeting anxiety in cancer patients and neurodegenerative diseases. Follows the FDA botanical drug pathway with IND submission underway in partnership with a leading U.S. hospital network. PUR102 is the lead botanical psilocybin candidate.
• PUR500 Series (PurQuest Pipeline) Engineered novel chemical entities (NCEs) designed from psychedelic scaffolds to stimulate neuron growth and enhance neural architecture without altering consciousness, while minimizing cardiovascular risks. Currently in pre-clinical development targeting unmet medical needs in neurological disorders.
• PUR102 Neuroplasticity and botanical psilocybin candidate targeting anxiety in cancer patients and palliative care. Currently in IND filing stage in partnership with a leading U.S. hospital network.
• PUR501 Novel non-hallucinogenic neuroplastogen (NCE) targeting Mild Cognitive Impairment (MCI). Currently in pre-clinical development.
• NeuroLabs 20,000 sq. ft. GMP-compliant facility purpose-built to support translational neuroscience research and scalable innovation in drug development and production. Located in Burlington, Ontario, and includes advanced scientific capabilities supporting 4P precision medicine.

Quantifiable outcome

• 300 biomarkers detected in 10 minutes vs traditional lab testing timelines
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• SpectroChip Global Inc.coreStrategic or Co-development Partner · 11 November 2025Exclusive strategic partnership between PurMinds and SpectroChip for development of point-of-care diagnostic solutions leveraging SpectroChip's photonic chip technology. Partnership expected to generate near-term revenue in 2026. The collaboration integrates SpectroChip's high-performance optical chips with PurMinds' diagnostic and therapeutic platforms.
• Pacific Software, Inc.coreStrategic or Co-development Partner · 3 November 2025Completion of change of control and reverse takeover (RTO) transaction effective November 2025. Pacific Software (OTC: PFSF), now dba PurMinds Enterprises, marks strategic entry into neurological health market with new management team and clinical-stage mission. Company pursuing OTCQX uplisting.
• OBIO (Ontario Bioscience Innovation Organization)minorGTM or Marketing PartnerOrganizational membership and participation in OBIO Investment Summit as presenting company. OBIO supports Ontario-based health science companies in advancing innovation and commercialization.
• Elevate IPminorOthersPartnership with Elevate IP program administered by Innovation, Science and Economic Development Canada (ISED) supporting intellectual property development and protection for Canadian innovators.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cybin: Clinical-stage neuropsychiatry company developing psychedelic-based therapeutics for mental health conditions. Direct competitor in psilocybin-derived therapeutics with similar regulatory pathway strategy.
• Atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapeutics for mental health disorders. Direct competitor in the psychedelic neuropharma space with multiple pipeline candidates similar to PurMinds' PUR100 and PUR500 series.
• Sage Therapeutics: Commercial-stage CNS biopharmaceutical company developing novel therapeutics for depression and neurological disorders. Comparable CNS therapeutic focus and regulatory pathway experience, though further along commercially.
• Compass Pathways: Clinical-stage mental health company developing psilocybin-based therapies for treatment-resistant depression. Most direct peer given PurMinds' PUR102 psilocybin program targeting anxiety in cancer patients and shared psychedelic therapeutic modality.
• GH Research: Clinical-stage biopharmaceutical company developing mebufotenin and other psychedelic compounds for treatment-resistant depression. Comparable scale and clinical-stage approach targeting similar CNS indications.
• MindMed: Clinical-stage neuropharma company developing psychedelic-inspired therapies for CNS disorders. Comparable pipeline-stage approach using LSD and MDMA-derived compounds, overlapping with PurMinds' neuroplastogen strategy.
• Bright Minds Biosciences: Clinical-stage neuropharma developing 5-HT receptor-targeted therapeutics for CNS disorders including epilepsy and depression. Highly comparable as the scientific advisory board member Dr. Alan Kozikowski is a co-founder of Bright Minds, signaling overlapping scientific approach.

Broad incumbents

• Cepheid (Danaher): Established molecular diagnostics company within Danaher, providing rapid PCR-based POCT systems to hospitals and healthcare facilities. Represents the dominant incumbent in biomarker-based rapid diagnostics that PurMinds' SpectroChip would compete against.
• Abbott Diagnostics: Global diagnostics incumbent with extensive POCT portfolio including i-STAT and other rapid diagnostic platforms. Represents the established competitive backdrop for PurMinds' SpectroChip diagnostic offering in hospital and clinical settings.
• QuidelOrtho: Major diagnostics company with broad point-of-care testing portfolio across multiple disease areas. Comparable as a POCT incumbent whose installed base and distribution scale PurMinds' SpectroChip partnership would compete with in healthcare settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/purminds
• YouTubeyoutube.com/@PurMinds
• LinkedInlinkedin.com/company/purminds-neuropharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Purminds